Your browser doesn't support javascript.
loading
Chinese Herbal Medicines for Restenosis After Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
Wu, Jiaming; Zhao, Lixian; Lin, Kaixuan; Lu, Liming; Luo, Chuanjin.
Afiliación
  • Wu J; Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine (Zhongshan Hospital of Traditional Chinese Medicine), Zhongshan, China.
  • Zhao L; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin K; Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine (Zhongshan Hospital of Traditional Chinese Medicine), Zhongshan, China.
  • Lu L; Clinical Research Centre, South China Research Centre for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Luo C; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
J Altern Complement Med ; 25(10): 983-992, 2019 Oct.
Article en En | MEDLINE | ID: mdl-31464515
ABSTRACT

Objectives:

This study evaluates the efficacy of Chinese herbal medicines after percutaneous coronary intervention (PCI).

Background:

PCI is the primary treatment for coronary atherosclerotic heart disease (CHD). However, many patients experience restenosis within 6 months after PCI. Chinese herbal medicines are widely used in patients after PCI. Clinical studies have found that Chinese herbal medicines may prevent restenosis.

Methods:

Eight databases were searched for randomized controlled trials (RCTs) investigating the use of Chinese herbal medicines after PCI. The search period was from the date of database inception to June 2017. We used the Cochrane risk of bias tool to estimate the methodological quality of the studies. The primary outcome was the restenosis rate, and secondary outcomes were the angina recurrence rate and major adverse cardiac events (MACEs). Data were analyzed with RevMan 5.3, and the quality of evidence was assessed with the GRAD approach.

Results:

Eleven RCTs with a total of 1,383 patients were included. The major outcome was the restenosis rate, and the results showed a significant effect of Chinese herbal medicines on reduction in the rate of restenosis (risk ratio [RR] = 0.46, 95% CI 0.35-0.60, p < 0.00001, I2 = 0%). Chinese herbal medicine treatment also decreased the angina recurrence rate (RR = 0.41, 95% CI 0.29-0.57, p < 0.00001, I2 = 0%). The results revealed a lower rate of MACEs in the Chinese medicine group than in the control group (RR = 0.49, 95% CI 0.34-0.71, p = 0.0001, I2 = 0%). We evaluated the quality of evidence with the GRADE system; the quality of evidence for the restenosis rate and angina was low, and the quality of evidence for MACEs was estimated to be moderate.

Conclusion:

According to existing research evidence, the use of Chinese herbal medicines may reduce the incidence of MACEs. Chinese herbal medicines may reduce restenosis and angina recurrence rates after PCI, but the evidence is limited.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Medicinas Tradicionales: Medicinas_tradicionales_de_asia / Medicina_china Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas Asunto principal: Complicaciones Posoperatorias / Medicamentos Herbarios Chinos / Reestenosis Coronaria / Intervención Coronaria Percutánea Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: J Altern Complement Med Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Medicinas Tradicionales: Medicinas_tradicionales_de_asia / Medicina_china Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas Asunto principal: Complicaciones Posoperatorias / Medicamentos Herbarios Chinos / Reestenosis Coronaria / Intervención Coronaria Percutánea Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: J Altern Complement Med Año: 2019 Tipo del documento: Article País de afiliación: China